{"id":45049,"date":"2024-03-05T11:33:30","date_gmt":"2024-03-05T10:33:30","guid":{"rendered":"https:\/\/www.maiwald.eu\/publikationen\/products-eligible-for-the-medical-use-format-under-the-epc-new-insights-managing-ip-2024\/"},"modified":"2024-03-05T11:33:30","modified_gmt":"2024-03-05T10:33:30","slug":"products-eligible-for-the-medical-use-format-under-the-epc-new-insights-managing-ip-2024","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/ko\/publications\/products-eligible-for-the-medical-use-format-under-the-epc-new-insights-managing-ip-2024\/","title":{"rendered":"Products eligible for the medical use format under the EPC: new insights, Managing IP 2024"},"content":{"rendered":"\n<p>In the latest article published by Managing IP, <a href=\"https:\/\/www.maiwald.eu\/ko\/team\/eva-ehlich\/\">Dr. Eva Ehlich<\/a> and <a href=\"https:\/\/www.maiwald.eu\/ko\/team\/anja-fux\/\">Dr. Anja Fux<\/a> summarise an EPO board ruling relating to substances and compositions in the context of medical use claims and how it could affect applicants\u2019 portfolio strategies<\/p>\n\n\n\n<p><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-45049","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen\/45049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen\/45049\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/media?parent=45049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}